Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre
- 163 Downloads
Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with 100% concordance to the main genotyping platform. Observed CYP2C19 genotypes were related to clopidogrel metabolism phenotypes and discussed in population context. Hereby, presented methodologies provide accurate CYP2C19 genotyping results in a relatively short time of one up to 12 h and may, therefore, find the relevant place in the field of genotype-guided antiplatelet therapy.
KeywordsCYP2C19 Pharmacogenetics Clopidogrel Genotyping Point of care
Part of this work was performed when Laboratory of Cardiogenomics was affiliated to the Department of Clinical and Molecular Pathology, University Hospital Olomouc. This work was partially supported by Grants: IGA PU: LF_2013_009, 2014_012, 2015_020, and LO1304.
- Beitelshees AL, Voora D, Lewis JP (2015) Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenom Pers Med 8:43–61Google Scholar
- Kishore A, Žižková V, Kocourková L et al (2015) A dataset of 26 candidate gene and pro-inflammatory cytokine variants for association studies in idiopathic pulmonary fibrosis: frequency distribution in normal Czech population. Front Immunol 22:476Google Scholar
- Ortega VE, Meyers DA, Bleecker ER (2015) Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenom Pers Med 8:9–22Google Scholar
- Stacey G, Ziaugra L, Tabbaa D (2009) SNP genotyping using the sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet 60:2.12.1–2.12.18Google Scholar
- US Food and Drug Administration (2010) FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug (online). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed 25 July 2016